How Do We Quantify Continuous Manufacturing Benefits?

Source: Sartorius

In this segment of the Bioprocess Online Live event Biopharma PAT: Gateway To Continuous Manufacturing, Paul Testa, EVP of Supply Chain and Operations at Kyowa Kirin North America and Barrett Fallentine, Director, Process & Product Development at Pharmatech Associates cover the intended, expected, and actual outcomes of continuous manufacturing initiatives in biopharma. They also tackle audience questions on modality-specific benefits of continuous manufacturing, and how much those benefits cross over from one product to the next.

View the full presentation on-demand here.


access the Video!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Bioprocess Online